London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the “Best Start-up Biotech Company” award at the OBN Awards 2018.
The award recognises IGEM as a UK registered start-up biotech company making a significant impact in the sector through news flow, successful fundraising and execution of a robust business plan. The ceremony on Thursday 11 October marked the 10th anniversary of the OBN Awards, which celebrate success stories from the UK life sciences industry over the past year.
Dr Tim Wilson, Chief Executive Officer of IGEM, commented: “We are thrilled that IGEM Therapeutics has been awarded “Best Start-up Biotech Company” at this year’s prestigious OBN Awards. The award recognises our efforts to treat cancer by developing novel immunoglobin E antibodies and our significant progress as a company over the last year.”
About IGEM Therapeutics
IGEM is a UK immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. Unlike immunoglobulin G (IgG), IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours.
Pre-clinical proof of concept has been obtained with two different IgE antibodies both showing significantly greater efficacy versus IgG comparators. IGEM is a spin out of King’s College London with financing from Epidarex Capital and has an ongoing collaboration with Dr. Sophia Karagiannis, a global leader in the understanding of IgE antibodies.
For further information visit www.igemtherapeutics.com
For more information please contact:
Chief Executive Officer
+44 (0)20 3078 9675
Communications advisor to IGEM Therapeutics:
Senior Managing Director
+44 (0)20 3727 1000